Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 14;39(2):105-109.
doi: 10.3760/cma.j.issn.0253-2727.2018.02.006.

[Efficacy analysis of unrelated cord blood transplantation in the treatment of refractory and relapsed adult acute leukemia]

[Article in Chinese]
X D Chu  1 , E L Chen, X Y Zhu, B L Tang, C C Zheng, K D Song, X H Zhang, J Tong, X Wan, L Zhang, H L Liu, Z M Sun
Affiliations

[Efficacy analysis of unrelated cord blood transplantation in the treatment of refractory and relapsed adult acute leukemia]

[Article in Chinese]
X D Chu et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Objective: To explore the clinical efficacy and safety of unrelated umbilical cord blood transplantation (UCBT) in the treatment of refractory and relapsed acute leukemia (AL) patients. Methods: The clinical data of 22 refractory and relapsed AL patients who were treated with UCBT as salvage therapy from November 2009 to May 2017 were retrospectively analyzed. All patients received a myeloablative conditioning regimen for prevention of graft-versus-host disease (GVHD) with cyclosporine A (CSA)/short course of mycophenolate mofetil (MMF). Results: ①Of 22 patients, 9 cases were male and 13 female. The median age was 23 (15-44) years and median weight of 52.5 (43-82) kg. All patients were transplanted with a median umbilical cord blood nucleated cells of 3.07 (1.71-5.30)×107/kg (by weight), the median CD34+ cells was 1.60 (0.63-3.04)×105/kg (by weight). ②The myeloid cumulative implantation rate was 95.5% (95%CI 45.2-99.7%) after transplantation of 42 d, with the median implantation time of 19 (13-27) d. The platelet cumulative implantation rate after transplantation of 120 d was 81.8% (95%CI 54.2-93.6%), the median implantation time of 42 (20-164) d. ③The incidence of Ⅱ-Ⅳ, Ⅲ-Ⅳ aGVHD and the 2 year cumulative incidence of cGVHD were 36.4%, 13.6% and 40.3% respectively. ④ The transplant related mortality (TRM) after transplantation of 180d was 22.7%, 2 year cumulative rate of relapse was 18.7% (95%CI 3.6-42.5%), 2 year disease-free survival rate (DFS) and overall survival rate (OS) were 53.7% and 58.1%, respectively. Conclusion: The preliminary results show that the use of UCBT is safe and effective for refractory and relapsed AL patients who fail to respond to conventional chemotherapy.

目的： 探讨非血缘脐血移植（UCBT）挽救治疗难治复发急性白血病（AL）患者的临床疗效和安全性。 方法： 回顾性分析2009年11月至2017年5月22例行UCBT挽救治疗的难治复发成人AL患者的临床资料，全部患者采用清髓性预处理方案，均采用环孢素A/短程霉酚酸酯方案预防GVHD。 结果： ①22例患者中男9例，女13例，中位年龄23（15~44）岁；中位体重52.5（43~82）kg。所有患者回输脐血有核细胞中位数为3.07（1.71~5.30）×107/kg（受者体重），CD34+细胞中位数为1.60（0.63~3.04）×105/kg（受者体重）。②移植后42 d髓系累积植入率为95.5%（95%CI 45.2%~99.7%），中位植入时间为19（13~27）d；移植后120 d血小板累积植入率为81.8%（95%CI 54.2%~93.6%），中位植入时间为42（20~164）d。③Ⅱ~Ⅳ度、Ⅲ~Ⅳ度急性GVHD发生率以及慢性GVHD 2年累积发生率分别为36.4%、13.6%和40.3%。④移植后180 d移植相关死亡率为22.7%；2年累积复发率为18.7%（95%CI 3.6%~42.5%），2年累积无病生存率及累积总生存率分别为53.7%和58.1%。 结论： 对于常规化疗无效的难治复发成人AL患者，初步结果显示采用UCBT安全、有效。.

Keywords: Drug resistance, neoplasm; Hematopoietic stem cell transplantation; Leukemia, acute; Relapse; Survival.

PubMed Disclaimer

Figures

图1
图1. 行非血缘脐血移植挽救治疗的22例难治复发急性白血病患者移植后180 d移植相关死亡统计曲线
图2
图2. 行非血缘脐血移植挽救治疗的22例难治复发急性白血病患者移植后2年累积复发统计曲线
图3
图3. 行非血缘脐血移植挽救治疗的22例难治复发急性白血病患者移植后2年总生存（A）和无病生存（B）曲线
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. 段 明辉, 张 岩, 张 梅, et al. CLAG方案治疗33例难治复发急性髓系白血病的疗效及安全性[J] 中华血液学杂志. 2016;37(7):571–575. doi: 10.3760/cma.j.issn.0253-2727.2016.07.006. - DOI - PubMed
    1. Ooi J. Cord blood transplantation in adults[J] Bone Marrow Transplant. 2009;44(10):661–666. doi: 10.1038/bmt.2009.282. - DOI - PubMed
    1. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond[J] Blood. 2013;122(4):491–498. doi: 10.1182/blood-2013-02-453175. - DOI - PMC - PubMed
    1. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis[J] Lancet Oncol. 2010;11(7):653–660. doi: 10.1016/S1470-2045(10)70127-3. - DOI - PMC - PubMed
    1. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study[J] Lancet. 2007;369(9577):1947–1954. doi: 10.1016/S0140-6736(07)60915-5. - DOI - PubMed